JP4256643B2 - Cartridge syringe, cartridge, and ophthalmic syringe set including the syringe - Google Patents

Description

[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a cartridge syringe used to administer an ophthalmic therapeutic agent, a cartridge, and an ophthalmic syringe set including the syringe.
[0002]
[Prior art]
As shown in FIG. 8, the conventional ophthalmic syringe has a liquid container 103 containing an ophthalmic therapeutic agent stored in a syringe body 101, and a plunger 105 is connected to the proximal end side of the syringe body 101. . A piston 107 is formed at the distal end of the plunger 105, and the piston 107 seals the chemical solution container 103 on the proximal end side of the chemical solution container 103. A rubber stopper 109 is provided at the tip of the chemical solution container 103 so that the needle can be inserted into the rubber stopper 109 when the ophthalmic syringe 100 is used.
[0003]
As described above, the conventional ophthalmic syringe is a disposable type in which the syringe body 101, the drug solution container 103, and the plunger 105 are integrated. Therefore, when it is discarded after use, a large amount of waste Was the cause.
[0004]
Further, ophthalmic syringes are sealed and packaged together with a syringe in a blister case to prevent contamination from microorganisms and the like, and further packaged in an outer box to protect the blister case and / or syringe. The blister case is made of plastic and has a size of about 16 cm in width, about 4.5 cm in length, and about 3 cm in height even if it is relatively small. The outer box is made of paper and is larger, and even a relatively small box has a width of about 16.5 cm, a length of about 5 cm, and a height of about 3.5 cm.
[0005]
Therefore, the packaged syringe becomes very large, and a large storage space is required to stock a large number of these syringes. The weight of the used ophthalmic syringe including the blister case and the outer box was about 28.5 g, and the presence of such packaging materials also caused an increase in waste.
[0006]
Since the problem of the storage space is generally easily decomposed by heat or light, it is remarkable in ophthalmic therapeutic agents that are often stored in a refrigerator. For example, in an ophthalmic syringe using an aqueous solution containing high molecular weight sodium hyaluronate as an active ingredient as an ophthalmic therapeutic agent, it is preferable to store it refrigerated because the viscosity decreases when the storage temperature is high. If it is large, a large space will be occupied in the refrigerator for storing medicines.
[0007]
In particular, with a syringe filled with a viscoelastic material used for cataract surgery, with the improvement of the technique of cataract surgery, as many as 15 cataract surgeries per day are performed in hospitals with many surgical cases. In such hospitals, it is necessary to have about 15 to 30 syringes stored in a large and bulky outer box as described above, and the problem of occupation of storage space in the refrigerator for storing medicine is serious. It was.
[0008]
[Problems to be solved by the invention]
The object of the present invention has been made in view of the background of the invention described in the above-mentioned prior art. By simply replacing the cartridge containing the ophthalmic therapeutic agent, only the cartridge is discarded after use, and the syringe itself can be used repeatedly. It is an object of the present invention to provide a simple cartridge syringe, a cartridge, and an ophthalmic syringe set including the syringe, and to reduce waste and secure a storage space for ophthalmic therapeutic agents through the provision of the cartridge syringe.
[0009]
[Means for Solving the Problems]
That is, the cartridge syringe of the present invention is a cartridge type syringe using a flanged cartridge filled with an ophthalmic therapeutic agent, and the syringe is provided so as to be connectable to a syringe body having a cartridge housing portion and a distal end side of the syringe body. Provided with a needle holding member and a plunger having a pusher at the distal end thereof so as to be slidable on the proximal end side of the syringe body, and a cartridge is provided at the connecting portion between the syringe body or the syringe body and the plunger. A one-touch loading mechanism capable of temporarily changing the position of the plunger so that the body can be loaded is provided.
[0010]
In the cartridge syringe, the one-touch loading mechanism is configured by connecting the syringe body and the plunger via a knuckle so that they can be bent, and the cartridge can be loaded by placing the plunger in a bent position. Good.
[0011]
Further, in the cartridge syringe, a cartridge holding portion which is slidable with respect to the syringe main body and urged toward the distal end of the syringe is provided around the plunger, and the cartridge is loaded in the cartridge storage portion. In this state, the cartridge holding part may be able to hold the cartridge by pushing the proximal end side of the cartridge.
Further, a cam surface is formed at the tip of the knuckle, and the knuckle can be rotated by sliding along the cam slide surface formed on the proximal end side of the syringe body, and the plunger is fully loaded. Even when it is possible to make the plunger bent by sliding the cam surface against the cam slide surface when the cam surface is bent to the side where the cam surface is formed in a state where the plunger is pulled Good.
[0012]
In addition, the plunger can be configured to be bent in only one direction.
Further, a flange support portion is formed on the proximal end side of the syringe body, and when the cartridge is loaded into the cartridge storage portion, the flange of the cartridge comes into contact with the flange support portion, and more than that of the cartridge. May be regulated.
[0013]
Further, two opposing locking claws projecting in the longitudinal direction are formed on the proximal end side of the syringe main body, and the two locking surfaces for regulating the orientation of the cartridge formed on the flange of the cartridge are When the cartridge is positioned so as to face the inner side of the locking claw, the loading of the cartridge is completed, and when the loading is completed, the locking surface of the cartridge is engaged with the inner side of the locking claw, thereby Free rotation around the direction axis may be restricted.
When the cartridge is loaded in the cartridge housing portion and the plunger is rotated so as to be linear with the syringe main body, the cartridge holding portion is biased toward the syringe main body. The cartridge flange may be held between the cartridge holding portion and the flange support portion.
[0014]
In the cartridge syringe, the one-touch loading mechanism may have a structure that can be disassembled by slightly rotating a plunger holder that holds a plunger around the longitudinal axis with respect to the syringe body.
In the cartridge syringe, the one-touch loading mechanism may have a structure in which a plunger holder that holds a plunger slides in a direction perpendicular to the longitudinal axis with respect to the syringe body.
[0015]
The present invention also relates to a cartridge filled with an ophthalmic therapeutic agent for use in combination with the above-described cartridge syringe of the present invention.
An ophthalmic syringe set according to the present invention includes any of the cartridge injectors described above and a cartridge filled with an ophthalmic therapeutic agent.
In the ophthalmic syringe set, the ophthalmic therapeutic agent filled in the cartridge may be a viscoelastic substance.
[0016]
In the ophthalmic syringe set, the ophthalmic therapeutic agent filled in the cartridge may be an aqueous solution containing hyaluronic acid or a salt thereof as an active ingredient.
In the ophthalmic syringe set, the ophthalmic therapeutic agent filled in the cartridge may be an aqueous solution containing sodium hyaluronate as an active ingredient.
In the ophthalmic syringe set, the capacity of the cartridge may be 1.0 mL to 20.0 mL.
[0017]
In the ophthalmic syringe set, an integral coupling structure may be provided between the pusher provided at the distal end of the plunger and the piston stopper provided on the proximal end side of the cartridge. .
In the ophthalmic syringe set, the integral coupling structure may include a push-in portion provided for the pusher and an insertion hole formed in the piston plug. In addition, the integral coupling structure may be configured by a screwing convex part in which a male screw provided to the pusher is formed and a screwing concave part formed in a piston plug and having a female screw.
Further, in the ophthalmic syringe set, the integral coupling structure may be constituted by a screwing convex part formed with a male screw provided to the pusher and a screwing concave part formed in a piston plug and formed with a female screw. .
[0018]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, embodiments of the present invention will be described with reference to the drawings. 1 is an exploded perspective view showing a cartridge syringe of the present invention and an ophthalmic syringe set equipped with the syringe, FIG. 2 is a side view showing a state when the cartridge is mounted, and FIG. FIG. 3B is a plan view of the state when the cartridge is mounted as seen from the longitudinal direction of the syringe.
[0019]
The cartridge syringe 1 is basically configured by including a syringe body 3, a needle holding member 5 provided on the distal end side of the syringe body 3, and a plunger 7 provided on the proximal end side of the syringe body 3. In the present specification, the side on which the needle of the cartridge syringe 1 is provided is the distal end side, and the opposite side is the proximal end side.
[0020]
The syringe body 3 is a cylindrical member, and a cartridge housing portion 11 having an inner diameter slightly larger than the outer diameter of the cartridge 9 is formed inside. A remaining amount confirmation window 13 is provided on the side peripheral surface of the syringe body 3, and a scale 14 is provided in the vicinity of the remaining amount confirmation window 13 for knowing the approximate remaining amount of the ophthalmic therapeutic agent. The remaining amount confirmation window 13 is provided for confirming the remaining amount of the ophthalmic therapeutic agent filled in the cartridge 9, and the shape and number thereof can be selected variously. Incidentally, the number of remaining amount confirmation windows 13 is preferably about 1 to 4 in view of the strength and visibility of the syringe body. However, in the embodiment shown in FIGS. Three are provided on the surface.
[0021]
A flange-shaped grip 15 is provided on the proximal end side of the syringe body 3. When the cartridge syringe 1 is used, the grip portion 15 is provided for the purpose of, for example, holding the syringe main body 3 and pushing the plunger 7 described later by holding the index finger and the middle finger. Therefore, various shapes can be selected as long as they are easy to put on a finger, but a polygonal shape that is a triangle or more in front view is preferable. Incidentally, in the embodiment shown in FIGS. 1 to 3, the holding portion 15 having a hexagonal shape in front view is used in consideration of stability when placed on a desk. Further, in this example, with the gripping portion 15 as a fulcrum, the weight on the plunger 7 side is increased, so that the tip of the needle inserted into the eye is free from other objects such as the surface of the desk or the bottom of the sterilization tray. Preventing contact. This prevents bacteria and foreign matter from adhering to the tip of the needle, thereby reducing the risk of postoperative inflammation (such as infection). In addition, a stand (such as a sterilization tray wall or tweezers) used to prevent the needle tip from contacting the surface of the desk or the bottom of the sterilization tray, which has been used in this type of conventional ophthalmic syringe (ophthalmic syringe). Is no longer necessary.
[0022]
A portion further proximal than the grip portion 15 is a connecting portion with a plunger 7 described later. The connecting portion is provided with a one-touch loading mechanism that allows the cartridge 9 to be loaded into the syringe body 3 with a simple operation. In the embodiment shown in FIGS. 1 to 3, a mechanism for connecting the syringe body 3 and the plunger 7 by the knuckle 17 is adopted as the one-touch loading mechanism. Two screw holes 21 are provided for attaching the fixing screw 19 serving as a moving shaft.
[0023]
In addition, two locking claws 23 are provided on the end surface on the proximal end side of the syringe main body 3 so as to protrude in the longitudinal direction and face each other. A flange support portion 26 is formed. The engaging claw 23 engages with two opposing engaging surfaces 27 that are cut in a straight line of a flange portion 25 formed at the proximal end of the cartridge 9 so that the cartridge 9 has its longitudinal axis. It plays the role of preventing the rotation around. Further, the flange support portion 26 abuts against the flange portion 25 of the cartridge when the cartridge is loaded, and functions to restrict further insertion of the cartridge.
[0024]
Further, as shown in FIGS. 4 (a) and 4 (b), the locking claw 23 is formed obliquely so that the flange portion 25 on which the locking surface 27 is formed is naturally guided between the two locking claws 23. The guide edge 48 may be formed. As a result, after the flange portion 25 of the cartridge 9 abuts against the guide edge 48, the cartridge 9 naturally rotates in a slanting direction due to its own weight as shown in FIG. It comes to fit naturally between the two locking claws 23. Further, instead of forming the locking claws 23 obliquely, the cartridge 9 may be tapered.
[0025]
The needle holding member 5 includes a needle 29 that directly administers the ophthalmic therapeutic agent, and a socket portion 33 that holds the needle 29 and fits into the small diameter portion 31 on the distal end side of the cartridge 9. A flange portion 34 is formed on the proximal end side of the socket portion 33, and the flange portion 34 is structured to be screwed and connected to a female screw engraved on the inner peripheral surface of the distal end side of the syringe body 3. Yes. In addition, you may employ | adopt the form which press-fits the socket part 33 in the small diameter part 31 of the front end side of the syringe main body 3, and / or the front end side of the cartridge 9. FIG.
[0026]
The plunger 7 is formed by forming a handle 35 at a base end side end portion of a round bar-shaped shaft body and a pusher 37 at a tip end side end portion. When the cartridge syringe 1 is used, the handle 35 is a portion that, for example, puts a thumb on this, holds the cartridge syringe 1 by a clamping action with the grip portion 15 and actually pushes the pusher 37. Therefore, the shape can be variously selected as long as it is suitable for pushing. Incidentally, the embodiment shown in FIGS. 1 to 3 employs a handle 35 having a circular shape when viewed from the front so that the center is somewhat depressed so as to be suitable for being pushed in with the thumb.
[0027]
The pusher 37 is a portion that abuts on the piston plug 39 that is initially located on the proximal end side of the cartridge 9 and that directly pushes the piston plug 39 toward the distal end side. By the way, in embodiment shown in FIGS. 1-3, it was set as the disk-shaped shape which made the diameter larger than the shaft. A push-in portion 41 is provided on the end surface on the front end side of the pusher 37. The push-in portion 41 is inserted into an insertion hole 43 formed on the base end side end surface of the piston plug 39 so that the piston plug 39 and the pusher 37 are integrally coupled, and at the same time, the piston plug 39 can move. Is responsible. Note that a mechanism for integrally coupling the piston plug 39 and the pusher 37 in this way is defined as an integral coupling structure in this specification.
[0028]
As described above, the one-touch loading mechanism is provided at the connecting portion between the syringe body 3 and the plunger 7. In the embodiment shown in FIGS. 1 to 3, a mechanism for flexibly connecting the syringe body 3 and the plunger 7 by the knuckle 17 is employed. The knuckle 17 is composed of a cylindrical holder portion 45 and two rotating blade pieces 47 extending like a bell from the tip side of the holder portion 45. Then, the fixing screw 19 is inserted from the outside of the rotating blade piece 47, and after passing through the convex washer 18 provided so that the convex side faces outward with respect to the inside of the rotating blade piece 47, the fixing screw 19 is screwed. The knuckle 17 can be rotated with respect to the syringe body 3 by being screwed into the hole 21. The washer 18 smoothes the rotation of the rotating blade piece 47, suppresses the generation of frictional heat generated when the rotating blade piece 47 rotates, and prevents the members from fusing together.
[0029]
An arcuate cam surface 24 is formed on one side of the distal end of the rotary blade 47, and this cam surface 24 slides on a cam slide surface 28 formed on the proximal end side of the syringe body 3. Thus, the knuckle 17, that is, the plunger 7 can be rotated. The cam surface 24 is not formed on the other side of the tip of the rotating blade piece 47, and therefore the plunger 7 can be rotated only on the side where the cam surface 24 is formed. Since the plunger 7 can be bent in only one direction as described above, the stability when the plunger 7 is pushed in is superior to a configuration that can be bent in both directions.
[0030]
The holder 45 has a structure in which a compression coil spring 49 and a part of the base end side of the cartridge holding part 51 which is provided with a tendency to protrude toward the distal end side by the compression coil spring 49 are accommodated. ing.
The cartridge holding portion 51 is a sleeve-like member having a through hole that is slidably fitted to the shaft body of the plunger 7 at the center, and has an outer diameter formed in multiple stages. The small diameter portion located on the proximal end side is slidably fitted in the fitting hole 53 formed on the proximal end surface of the holder portion 45, and the large diameter portion located on the distal end side is directly in the cartridge 9. It abuts against the end surface of the flange portion 25 and exerts a pressing action, and a pusher receiving hole 55 formed inside abuts against the proximal end surface of the pusher 37 to prevent the plunger 7 from falling off. Further, the middle diameter portion located in the middle has a function as a base of the compression coil spring 49.
[0031]
The knuckle 17, the compression coil spring 49, and the cartridge holding part 51 configured as described above are assembled to the syringe body 3 and the plunger 7 as shown in FIGS. Can be attached freely.
[0032]
Further, the above-mentioned components of the cartridge syringe 1 excluding the needle holding member 5, specifically, the syringe body 3, the plunger 7, the knuckle 17 constituting the one-touch loading mechanism, the cartridge holding portion 51, etc., should be used repeatedly. It is made of strong material that can be used. As an example, a metal material such as titanium, stainless steel, aluminum, or an alloy containing these as a main component can be applied. In particular, titanium having excellent chemical resistance, heat resistance, weight reduction, strength, and the like can be said to be a suitable material. Of course, if there are other metal materials having the same performance as these and non-metal materials such as synthetic resins, the materials can be used.
[0033]
Next, the cartridge 9 which is loaded in the cartridge syringe 1 of the present invention and is a component of the ophthalmic syringe set of the present invention will be described. As shown in FIGS. 1 to 3, the cartridge 9 has a small-diameter portion 31 by slightly constricting the distal end portion of the cylindrical cartridge main body 57 and the flange portion 25 with the locking surface 27 at the proximal end portion. , And after the ophthalmic therapeutic agent is filled, the proximal end side open surface of the cartridge main body 57 is closed by a piston plug 39 that functions as a piston for pushing out the ophthalmic therapeutic agent. As the material of the cartridge body 57, glass having excellent visibility, polyolefin plastics such as polyethylene and polypropylene, plastics such as polyethylene terephthalate and polycarbonate, etc. can be applied, and glass should be used in consideration of the stability of the contents. Is preferred. Reference numeral 59 denotes a rubber plug that closes a small hole formed at the center of the small diameter portion 31. The use of a cartridge having a small-diameter portion with a narrowed tip portion eliminates the need for an inverted needle-shaped needle as shown in FIG. When the needle is inserted into the rubber stopper, it is possible to prevent rubber fragments from entering the medicine.
[0034]
The capacity of the cartridge 9 is 1.0 mL to 20.0 mL, and the capacity of the ophthalmic therapeutic agent that can be filled in the cartridge 9 is 0.1 mL to 20.0 mL. Incidentally, when an aqueous solution containing sodium hyaluronate as an active ingredient is filled as an ophthalmic therapeutic agent, the volume of the ophthalmic therapeutic agent to be filled is 0 in terms of the amount used in surgery and the filling efficiency into the cartridge 9. It is preferable to be within the range of 4 mL to 2.0 mL.
[0035]
Examples of ophthalmic therapeutic agents used in the present invention include viscoelastic substances, perfusates, mydriatics, miotic agents, antibiotics, antibacterial agents, anti-inflammatory agents, and local anesthetics. Examples of the viscoelastic substance include an aqueous solution containing sodium hyaluronate, chondroitin sulfate, chitin, chitosan, collagen, cellulose derivatives, or a mixture of the above components as an active ingredient. The perfusate is an isotonic aqueous solution (containing monovalent and / or divalent ions such as sodium ion, potassium ion, calcium ion, magnesium ion, etc., pH is 6.4-8.2, glutathione, glucose May be contained).
[0036]
Examples of mydriatics include ebinephrine or synergistic drugs (including derivatives). Examples of miotic agents include acetylcholine and synergistic drugs (including derivatives and cholinesterase inhibitors). Antibiotics include aminoglycosides and β-lactam antibiotics. Examples of antibacterial agents include quinolone synthetic antibacterial agents. Furthermore, examples of anti-inflammatory agents include steroids and non-steroidal anti-inflammatory agents. Furthermore, examples of the local anesthetic include lidocaine and synergistic drugs (including derivatives).
[0037]
Such an ophthalmic therapeutic agent is, for example, locally administered to a diseased site or inserted with an intraocular lens as a drug for the treatment and / or prevention of ophthalmic diseases in mammals including humans, particularly cataracts. It can be used as an ophthalmic surgery auxiliary agent.
As the salt of hyaluronic acid, a sodium salt is usually used, but a potassium salt or the like may be used. The hyaluronic acid or salt thereof that can be used in the present invention preferably has a molecular weight of 500,000 to 8,000,000, more preferably 500,000 to 3.9 million.
[0038]
Further, those having an endothelium protecting effect are preferably those having a molecular weight in the range of 500,000 to 1,200,000 and a molecular weight in the range of 1.9 million to 3.9 million when used for holding the anterior chamber. Furthermore, in terms of operability at the time of surgery, there are some operators who prefer a molecular weight in the range of 1.5 million to 3.9 million, such as different molecular weights depending on the purpose etc. Yes. In addition, the molecular weight used in this specification shall mean a viscosity average molecular weight.
[0039]
The concentration of the hyaluronic acid or a salt thereof is preferably in the range of 200 to 5,000 μg / mL. Incidentally, if the concentration of hyaluronic acid or a salt thereof is less than 200 μg / mL or exceeds 5,000 μg / mL, the corneal epithelial layer spreading promoting action is lowered, which is not preferable. In the case of an ophthalmic liquid preparation, if it exceeds 5,000 μg / mL, handling and administration (application) become difficult, such being undesirable.
Further, when an aqueous solution containing hyaluronic acid or a salt thereof as an active ingredient is used as an ophthalmic therapeutic agent, other additives other than hyaluronic acid, for example, sodium chloride, disodium hydrogen phosphate, monopotassium hydrogen phosphate, etc. Alternatively, anti-inflammatory agents such as chondroitin sulfate and glycyrrhizin may be added as appropriate.
[0040]
When the ophthalmic therapeutic agent using hyaluronic acid or a salt thereof used in the present invention is applied clinically as an ophthalmic liquid preparation, the molecular weight of the phosphate buffered physiological saline is 500,000 to 8 million, preferably 500,000 to 0.1 to 2 mL of 3.9 million sodium hyaluronate dissolved at a concentration of 200 to 5,000 μg / mL is administered at a time. A number of experiments have already been conducted on the safety (toxicity / non-inflammatory) of hyaluronic acid, and its safety has been confirmed. For example, it has been confirmed that there is no irritation or antigenicity in eye toxicity by experiments using rabbits (Norio Ueno et al .: Bulletin of Japanese Ophthalmology) 35 , 584 (1984) and the same 35 803 (1984)).
[0041]
The cartridge syringe 1 of the present invention and the ophthalmic syringe set including the syringe have the structure as described above, and the operation thereof will be described below. First, the handle 35 is pulled to pull the plunger 7 to the most proximal position. In this state, when the plunger 7 is bent to the side where the cam surface 24 is formed, the cam surface 24 slides on the cam slide surface 28, so that the plunger 7 can be rotated.
[0042]
Also, a cartridge 9 is prepared separately from the cartridge syringe 1, and the cartridge 9 is inserted from the open end on the proximal end side of the syringe main body 3 and loaded into the cartridge storage portion 11. At this time, the locking surface 27 formed on the flange portion 25 of the cartridge 9 is aligned so as to be engaged with the inside of the locking claw 23 formed on the syringe body 3.
[0043]
Then, the plunger 7 is rotated in the reverse direction and is positioned so as to be linear again with respect to the syringe body 3. When the plunger 7 is positioned linearly, the cartridge holding portion 51 is moved to the tip side by the urging force of the compression coil spring 49, and the flange portion 25 of the cartridge 9 is interposed between the cartridge holding portion 51 and the flange support portion 26. It will be retained. In this way, the cartridge 9 is fixed to the syringe body 3.
[0044]
Next, the plunger 7 is pushed in the axial direction, or rotated in a predetermined direction around the axial line, and the pushing portion 41 provided in the pusher 37 is inserted into the insertion hole 43 formed in the piston plug 39 in the cartridge 9. The piston plug 39 and the plunger 7 are coupled so that they can move together. Then, the rubber stopper 59 fitted to the tip of the cartridge 9 is removed, and the needle holding member 5 is attached to the small diameter portion 31 of the cartridge 9 from the tip side of the syringe body 3, whereby the cartridge syringe 1 is as shown in FIG. It becomes ready for use.
[0045]
In use, for example, the index finger and the middle finger are put on the grip portion 15 of the syringe body 3, and the plunger 7 is pushed toward the distal end side, for example, by putting the thumb on the handle 35 of the plunger 7. When the plunger 7 is pushed in, the piston plug 39 fixed to the pusher 37 via the push-in portion 41 and the insertion hole 43 also moves toward the distal end side, and the ophthalmic therapeutic agent filled in the cartridge main body 57 is It is pushed out through the needle 29 and used for administration of an ophthalmic therapeutic agent.
[0046]
When the plunger 7 is bent, the plunger 7 is pulled to the most proximal position because the peripheral surface of the pusher 37 is the inner peripheral surface of the syringe body 3 or the cartridge body when the plunger 7 is pushed to some extent. This is because the plunger 7 cannot rotate because it abuts against the inner peripheral surface of 57.
By the way, such a structure prevents the accident that the plunger 7 is unexpectedly bent and the cartridge 9 is dropped during use, contrary to the intention of the operator.
[0047]
Next, another embodiment of the present invention will be described. FIG. 5 shows that the cartridge 9 can be loaded into the cartridge housing portion 11 from the relatively large receiving opening 61 formed in the syringe body 3 without basically releasing the connection between the syringe body 3 and the plunger 7. It is an embodiment. Even if such a configuration is adopted, it is the same in that the cartridge 9 can be stored in the cartridge storage portion 11 with a simple operation, and is included in the one-touch loading mechanism used in this specification.
[0048]
In the embodiment shown in FIG. 5, the grip portion 15 is configured separately from the syringe main body 3, but is fixed to the syringe main body 3 as in the embodiment shown in FIGS. It is also possible to do.
[0049]
However, in the case of the embodiment shown in FIG. 5, the syringe body 3 tends to be structurally long, and this embodiment has been improved in the embodiment shown in FIGS. It is an embodiment shown.
[0050]
That is, FIG. 6 shows still another embodiment of the one-touch loading mechanism. Among them, the one shown in FIG. 6 (a) is an exploded view in which the syringe body 3 and the plunger 7 can be removed by a simple operation. It is an embodiment of a formula. Specifically, the engaging claw 63 is provided at the proximal end portion of the syringe body 3, and the engaging groove 65 that engages with the engaging claw 63 is provided on the plunger holder 67, so that the plunger holder 67 is turned a little. The plunger 7 can be removed from the syringe body 3.
[0051]
FIG. 6B shows a slide type embodiment in which the plunger 7 can be shifted with respect to the syringe body 3 in a direction orthogonal to the axial direction by a simple operation. Specifically, by providing the guide rail 69 on the syringe body 3 side and the slider 73 engaging the guide rail 69 on the plunger holder 71 side holding the plunger 7, the plunger 7 can be shifted to the side of the syringe body 3. It is something that can be done.
[0052]
Another embodiment of the integral coupling structure is the embodiment shown in FIG. This is provided with a threaded projection 75 having a male thread formed on the pusher 37 and a threaded recess 77 having a female thread formed on the piston plug 39. Incidentally, in the case of such a configuration, the plunger 7 and the piston plug 39 are more firmly coupled by the screwing operation of the plunger 7.
[0053]
【The invention's effect】
According to the invention described in claims 1 to 10, since the cartridge syringe can be used frequently, the waste becomes only the cartridge, and the waste can be reduced by a considerable amount as compared with the case of the conventional disposable syringe. it can. In addition, the one-touch loading mechanism makes it possible to load the cartridge into the cartridge syringe in a short time with a simple operation. Furthermore, since the sealed packaging in the blister case to prevent contamination from microorganisms and the like only needs to be targeted for the cartridge, the blister case and the outer box can be miniaturized, and the storage space in the medicine storage refrigerator can be occupied. Problems are also avoided. Accordingly, in order to reduce the amount of waste and the storage space, it is essential to supply only a cartridge filled with an ophthalmic therapeutic agent.
Incidentally, in the present invention, the effect of reducing the volume of the blister case and the outer box and the weight of the waste was confirmed as compared with the conventional one.
[0054]
According to the third aspect of the present invention, since the cartridge is firmly held in the cartridge housing portion, there is no risk that the cartridge is detached from the cartridge housing portion.
According to the fourth aspect of the present invention, the cartridge can be easily inserted and removed by bending the plunger.
[0055]
According to the fifth aspect of the present invention, the stability when the plunger 7 is pushed in is superior to the structure that can be bent in both directions.
According to the sixth aspect of the invention, when the cartridge is loaded into the cartridge housing portion, the cartridge loading depth can be reliably regulated.
[0056]
According to the seventh aspect of the present invention, since the rotation around the longitudinal axis of the cartridge is prevented, the cartridge does not move when the plunger is pushed in, and the medicine can be stably injected.
According to the eighth aspect of the invention, since the flange of the cartridge is held between the cartridge holding portion and the flange support portion, the cartridge can be prevented from wobbling in the cartridge storage portion.
[0057]
According to the invention described in claim 12, the excellent effect can be realized in an ophthalmic syringe set.
Moreover, according to the invention of Claims 13-15, it becomes possible to use widely for treatment, prevention, etc. of ophthalmic diseases, such as a cataract, from the efficacy and safety | security.
[0058]
According to the invention described in claim 16, the cartridge can be selected so as to be suitable for the amount of the ophthalmic therapeutic agent used in the operation, and an appropriate amount of the ophthalmic therapeutic agent can be used at a time.
Further, according to the invention of claim 17, 18 or 19, since the movement of the plunger appears as the movement of the piston plug as it is, the operability of the plunger and the follow-up performance of the piston plug are improved, and a small amount of ophthalmic therapeutic agent can be administered. Can also respond.
[Brief description of the drawings]
FIG. 1 is an exploded perspective view showing a cartridge syringe of the present invention and an ophthalmic syringe set equipped with the syringe.
FIG. 2 is a side view showing a state when a cartridge is loaded into the cartridge syringe of the present invention.
3A is a plan view showing a state after the cartridge is mounted, and FIG. 3B is a plan view of the state when the cartridge is mounted as viewed from the longitudinal direction of the syringe.
4A is a perspective view showing a state immediately before a cartridge flange is guided by a guide edge and automatically enters between two locking claws, and FIG. 4B is a diagram illustrating locking of the cartridge flange. It is a perspective view which shows the state which the surface entered between the latching claws.
FIG. 5 is an exploded perspective view showing another embodiment of the present invention.
FIG. 6 is a plan view showing two other embodiments of the one-touch loading mechanism.
FIG. 7 is a cross-sectional view showing another embodiment of an integral connection structure.
8A is a side view showing a state before use in a conventional disposable syringe, and FIG. 8B is a side view showing a state after use in a conventional disposable syringe.
[Explanation of symbols]
1 cartridge syringe
3 Syringe body
5 Needle holding member
7 Plunger
9 Cartridge
11 Cartridge storage
13 Remaining amount confirmation window
14 Scale
15 gripping part
17 Knuckles
18 Washer
19 Fixed screw
21 Screw holes
23 Claw
24 Cam surface
25 Flange
26 Flange support
27 Locking surface
28 Cam slide surface
29 needles
31 Small diameter part
33 Socket part
34 Flange
35 Handle
37 Pusher
39 Piston stopper
41 Push-in part
43 Insertion hole
45 Holder part
47 Rotating blade
48 Guide edge
49 Compression coil spring
51 Cartridge holder
53 Mating hole
55 Pusher receiving hole
57 Cartridge body
59 Rubber stopper
61 Receiving opening
63 engaging claw
65 engaging groove
67 Plunger holder
69 Guide rail
71 Plunger holder
73 Slider
75 Threaded projection
77 Threaded recess
100 Ophthalmic syringe
101 Syringe body
103 Chemical container
105 Plunger
107 piston
109 Rubber stopper

Claims (14)

   In a cartridge type syringe using a flanged cartridge filled with an ophthalmic therapeutic agent, the syringe has a syringe main body having a cartridge housing portion, a needle holding member provided to be connectable at a distal end side of the syringe main body, and a syringe main body And a plunger having a pusher at the distal end thereof. The syringe main body or a connecting portion between the syringe main body and the plunger is temporarily mounted so that a cartridge can be loaded into the syringe main body. The cartridge syringe is provided with a one-touch loading mechanism capable of changing the position of the plunger, and the one-touch loading mechanism is configured by connecting the syringe body and the plunger via a knuckle so as to be bent. By making the plunger bent The cartridge can be loaded, and a cam surface is formed at the tip of the knuckle, and the knuckle is rotatable by sliding along the cam slide surface formed on the proximal end side of the syringe body. When the plunger is pulled to the side where the cam surface is formed with the plunger fully pulled, the cam surface slides with respect to the cam slide surface so that the plunger is bent. A cartridge syringe characterized in that it is possible.  2. The cartridge syringe according to claim 1, wherein the plunger can be bent in only one direction.  3. The flange support portion according to claim 1 or 2, wherein a flange support portion is formed on the proximal end side of the syringe main body, and the cartridge flange abuts against the flange support portion when the cartridge is loaded into the cartridge storage portion. A cartridge syringe characterized in that further insertion of the cartridge is restricted.  In any one of Claims 1-3, the two opposing nail | claws which protrude in the longitudinal direction are formed in the base end side of the said syringe main body, The direction of the cartridge formed in the flange of the said cartridge is changed. When the two locking surfaces to be regulated are positioned so as to face the inside of the locking claw, the loading of the cartridge is completed, and when the loading is completed, the locking surface of the cartridge is inside the locking claw Engaging with the cartridge restricts free rotation about the longitudinal axis of the cartridge.  5. The cartridge holder according to claim 1, wherein when the plunger is rotated so as to be linear with the syringe main body in a state where the cartridge is loaded in the cartridge storage portion, the cartridge holding portion is The cartridge syringe is characterized in that the flange of the cartridge is held between the cartridge holding portion and the flange support portion by being biased to the side.  2. The cartridge syringe according to claim 1, wherein the one-touch loading mechanism has a structure in which a plunger holder holding a plunger is slid in a direction perpendicular to the longitudinal axis with respect to the syringe body.  An ophthalmic syringe set comprising the cartridge syringe according to claim 1 and a cartridge filled with an ophthalmic therapeutic agent.  8. The ophthalmic syringe set according to claim 7, wherein the ophthalmic therapeutic agent filled in the cartridge is a viscoelastic substance.  8. The ophthalmic syringe set according to claim 7, wherein the ophthalmic therapeutic agent filled in the cartridge is an aqueous solution containing hyaluronic acid or a salt thereof as an active ingredient.  8. The ophthalmic syringe set according to claim 7, wherein the ophthalmic therapeutic agent filled in the cartridge is an aqueous solution containing sodium hyaluronate as an active ingredient.  The ophthalmic syringe set according to claim 7, wherein the cartridge has a capacity of 1.0 mL to 20.0 mL.  In any one of Claims 7-11, the integral coupling structure which couple | bonds both integrally is provided between the pusher provided in the front-end | tip of the said plunger, and the piston stopper provided in the base end side of the said cartridge. An ophthalmic syringe set characterized by the above.  13. The ophthalmic syringe set according to claim 12, wherein the integral coupling structure includes a push-in portion provided for the pusher and an insertion hole formed in the piston plug.  13. The integral coupling structure according to claim 12, wherein the integral coupling structure includes a threaded convex portion formed with a male screw provided to the pusher and a threaded concave portion formed in a piston plug and formed with a female screw. Ophthalmic syringe set.

Images